On the contrary, gemcitabine administered mice showed significant (P < 0.05) decreases of the splenic TNF-α and IL-1β, and nonsignificant but dramatic decreases of splenic IL-10 contents as compared with tumor-bearing control mice, respectively (Table 3). The gene discussed is IL10; the disease is neoplasm.